Get the Stockscreener App
26.99
1.81%
0.48
Instil Bio Inc stock is traded at $26.99, with a volume of 65,118.
It is up +1.81% in the last 24 hours and down -5.10% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$26.51
Open:
$26.85
24h Volume:
65,118
Relative Volume:
0.21
Market Cap:
$182.20M
Revenue:
-
Net Income/Loss:
$-74.14M
P/E Ratio:
-2.3696
EPS:
-11.39
Net Cash Flow:
$-65.70M
1W Performance:
-3.05%
1M Performance:
-5.10%
6M Performance:
+22.02%
1Y Performance:
+115.92%
1-Day Range:
$26.36
$27.84
1-Week Range:
$23.82
$29.48
52-Week Range:
$10.80
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
26.99 | 194.79M | 0 | -74.14M | -65.70M | -11.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Perform |
| Apr-12-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
Market reaction to Instil Bio Inc.’s recent news2025 Price Action Summary & Step-by-Step Trade Execution Guides - Newser
Using data filters to optimize entry into Instil Bio Inc.July 2025 Catalysts & Long-Term Capital Growth Strategies - Newser
How to interpret RSI for Instil Bio Inc. stock2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - Newser
Instil Bio Posts Wider Loss in Q2 - AOL.com
Instil Bio's Institutional Ownership: A Catalyst for Governance, Capital Allocation, and Future Performance - AInvest
Instil Bio's Institutional Ownership and Potential Impact on Stock Price - AInvest
Citizens JMP Analyst Reiterates Hold Rating on Instil Bio - AInvest
Best data tools to analyze Instil Bio Inc. stockMarket Sentiment Review & Long-Term Safe Return Strategies - Newser
H.C. Wainwright Maintains Instil Bio(TIL.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛
Intraday Charts Show Spike in Instil Bio Inc. ActivityJuly 2025 Market Mood & Free AI Powered Buy and Sell Recommendations - 선데이타임즈
Instil Bio's Promising Trial Data and Financial Outlook Earns Buy Rating from H.C. Wainwright - AInvest
Instil Bio's (TIL) $125 Price Target Maintained by HC Wainwright Despite Recent Rating Changes. - AInvest
Instil Bio Receives Buy Rating Amid Promising Trial Data and Strong Financial Outlook - TipRanks
Instil Bio: HC Wainwright Raises PT to $125, Reiterates Buy Rating - AInvest
Instil Bio stock rating reiterated by JMP, awaits more robust results - Investing.com Australia
Instil Bio Inc.’s volatility index tracking explainedMarket Rally & Expert-Curated Trade Recommendations - Newser
Will Instil Bio Inc. stock benefit from interest rate changesDollar Strength & Reliable Breakout Forecasts - Newser
Chart based analysis of Instil Bio Inc. trends2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Instil Bio Inc. Added to High Probability Setup ListJuly 2025 EndofMonth & AI Driven Stock Price Forecasts - thegnnews.com
Is Instil Bio Inc. reversing from oversold territoryMarket Rally & Real-Time Volume Analysis Alerts - Newser
Instil Bio Reports Wider Q2 Loss Amid Escalating R&D Costs - AInvest
Instil Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Instil Bio Posts Wider Loss in Q2, Cash Reserves Decline to $103.6 Million - AInvest
Kindly Md, Inc. shares rise 2.80% premarket after Instil Bio reported strong clinical efficacy and safety data for ORIC-944. - AInvest
Instil Bio, Inc. SEC 10-Q Report - TradingView
Applying chart zones and confluence areas to Instil Bio Inc.July 2025 News Drivers & Daily Technical Forecast Reports - Newser
Instil Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Instil Bio reports Q2 financials, '2510 IND cleared by US FDA. - AInvest
Instil Bio Inc. Testing Reversal Zone on Weekly Chart2025 Performance Recap & Safe Capital Allocation Plans - beatles.ru
Press Release: Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
Sectors Driving Future Growth for Instil Bio Inc. Stock [2025 Top Decliners]Comprehensive Market Scan Insights - Newser
Published on: 2025-08-12 21:39:14 - Newser
Can Instil Bio Inc. grow without dilutionDual Momentum Investment Alerts - classian.co.kr
What MACD and RSI say about Instil Bio Inc.Buy Alert Based on RSI and Volume - Newser
How to manage a losing position in Instil Bio Inc.Free AI-Powered Trade Planning with Indicators - Newser
Institutional Tools Highlight Unusual Flow in Instil Bio Inc.Profit Focused Stock Screener Results Released - beatles.ru
When is the best time to buy Instil Bio Inc. stockSmart Chart Forecasting with AI Algorithms - Newser
Using RSI to spot recovery in Instil Bio Inc.Market Forecast Summary Over Multi-Year Period - Newser
Instil Bio TIL Q2 2025 Earnings Preview Upside Potential Driven by New Product Launch - AInvest
Why Instil Bio Inc. is moving todayAI Powered Stock Market Trend Forecast - Newser
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):